[Frontiers in Bioscience E4, 516-528, January 1, 2012]
Hair dye use and risk of human cancer
Yawei Zhang1, Christopher Kim1, Tongzhang Zheng1
1
TABLE OF CONTENTS
1. ABSTRACT
Over 50% of the adult population will use hair dyes at some point in their lifetimes. Hair dyes consist of various chemicals and the composition of these chemicals vary by hair dye types. Chemicals p-phenylenediamine and aminophenyl have been suggested as possible carcinogens or mutagens in experimental studies. The scientific community has been interested in this potential public health impact and the results of published epidemiological studies are summarized here. The current evidence provides limited evidences on the association between personal hair dye use and human cancer risk, except for the possibility of hematopoietic cancers and to a lesser extent, bladder cancer. Risk appears to be affected by time period of use and by specific genetic polymorphisms. Future studies should investigate potential gene and environment interaction to assess possible genetic susceptibility. Several methodological issues should also be considered in future studies including completed hair dye use information such as on timing, duration, frequency and type of hair dye product use.
2. INTRODUCTION
It is estimated that the hair-coloring product sales worldwide is about $12 billion per year and that up to 50% of the adult population of high-resource countries use hair colorants (1). Hair-coloring products include permanent, semipermanent and temporary dyes that vary by chemical formulation and are distinguished mainly by how long they last and whether they penetrate the hair shaft. Permanent dyes represent about 80% of the hair color market (1). Some compounds in hair dyes have been reported to be mutagenic or carcinogenic in bioassay systems (2). Many oxidative dye products were reformulated in the early 1980s to eliminate ingredients that produced tumors in experimental bioassay studies. Although it is unclear whether the current compounds have carcinogenic effects or can affect overall immune response, paraphenylenediamine (PPD), a major arylamine currently used in most hair dyes, has been suggested as a putative carcinogen (3). In addition, it has been found that many permanent hair dyes are contaminated with 4-aminobiphenyl (4-ABP), a recognized human carcinogen (4).
During the past three decades, the general public and the scientific community have shown great interest in the potential health impact from personal use of hair dyes. Epidemiological studies have been conducted to investigate the relationship between hair dye use and human cancer risk. The reported results, however, have been inconsistent and the relationship is varied by cancer type. The purpose of this review is to summarize the current understanding of the relationship between personal hair dye use and risk of human cancer by specific cancer types.
3. BLADDER CANCER
A total of 11 case-control studies (5-15) and three cohort studies (16-18) have investigated the relationship between personal hair dye use and risk of bladder cancer (Table 1). These investigations assessing hair dye use and risk of bladder cancer have produced inconsistent results. Many of the studies involved small population sizes and/or incomplete hair dye usage information.
One large population-based case-control study including 2,982 cases and 5,782 controls reported an increased risk of bladder cancer associated with ever using black hair dye product for both men and women (OR=1.4, 95% CI: 1.0,1.9) (8). Another population-based case-control study involving 897 cases and equal number of controls found a two-fold increased risk of bladder cancer among women who had used permanent hair dyes at least once a month, and the risk increased to 3.3-fold (95% CI: 1.3,8.4) for women who were regular (at least monthly) users for at least 15 years (15). The cohort studies generally reported no association between bladder cancer and hair dye use (16-20)
Three meta-analysis studies have been published since 2005 assessing risk of bladder cancer and exposure to hair dyes (21-23). A study by Huncharek and Kupelnick (21), which had significant exclusion criteria (which limited the meta-analysis to a mere seven studies) and a unique weighted method of analyzing the data, suggested that there is a relative risk between 1.22 (95% CI: 1.11, 1.51) and 1.50 (95% CI: 1.30, 1.98). Another two meta-analysis studies by Takkouche et al. (22) and Kelsh et al (23) found no association between bladder cancer and hair dye use.
To date, very few studies have investigated whether genetic susceptibility modify the relationship between personal hair dye use and risk of bladder cancer. Gago-Dominguez et al. (15) examined permanent hair dyes and bladder cancer risk by N-acetyltransferase-2 (NAT2) phenotype among female in the Los Angeles Bladder Cancer Study. Among NAT2 slow acetylators, exclusive use of permanent hair dyes was associated with 2.7-fold increased risk of bladder cancer (95% CI: 1.0,7.2), and the risk appeared to increase with increasing duration and frequency of use of hair dye products. Hair dye use was not associated with bladder cancer risk among NAT2 fast acetylators (OR=1.1, 95%CI: 0.4,2.7). In 2003, Gago-Dominguez et al. (3) also examined the effects of several other potential arylamine-metabolizing genotypes/phonetypes (GATM1, GSTT1, GSTP1, CYP1A2). The study found a 2.5-fold increased risk of bladder cancer associated with permanent hair dye use among women exhibiting CYP1A2 'slow' phenotype but not among women exhibiting CYP1A2 'rapid' phenotype. No such modifying effects were observed for GSTT1, GSTM1, and GSTP1 genotypes. Another study reported no such increase in risk by any NAT1, NAT2, GSTM1, GSTM3, GSTP1, GSTT1, or CYP1A2 genotype (13).
4. BREAST CANCER
A total of 11 case-control studies (7, 24-34) and four cohort studies (16, 18-20, 35) have investigated the relationship between personal hair dye use and risk of breast cancer (Table 2). Nearly all of the studies have yet to suggest a conclusive no association between breast cancer risk and exposure to hair dyes with the exception of one case-control study (34).
No association between breast cancer and hair dye use was noted in most case-control studies (7, 24-26, 28-33). When some of these studies estimated frequency, duration, or dose-response relationships, no significant results exists for most studies. Moreover, several studies lacked information critical to performing some of these analyses (31, 34).
When assessing for duration of use and type of hair dye use, positive associations sometimes were seen. In a study by Cook et al (32), 2.5-fold (95% CI: 1.6, 3.9) increased risk was found among women who reported using any hair dye products after bleaching. A significantly increased risk was also observed for women who reported using any rinse (OR=1.7, 95% CI: 1.2, 2.5) and any frosting/tipping (OR=1.5, 95% CI: 1.2, 2.0) before applying hair dye products. Among women who reported using two or more types of hair dye products, a 3.1-fold (95%CI: 1.6, 6.1) increased risk of breast cancer was observed for those used hair dyes for 90 or more total episodes during their lifetime. In the Zheng et al. study (33) individuals using exclusively semi-permanent types of hair coloring products, some ORs were elevated. Also, an increase in risk was noted for women who changed hair colors multiple times (28)
The one study which suggested a strong association is the Petro-Nustas et al. (34) case-control study in Jordan women. They reported that women who had ever used hair dye products experienced an 8.6-fold (95 CI: 3.3, 22.3) increased risk of breast cancer compared to those who had never used hair dye products. However, this study had several limitations, including a convenience sample of controls, lack of detailed information on hair dye use, and most importantly, is based on a very small sample size.
5. NON-HODGKIN LYMPHOMA
Fourteen case-control studies and three cohort studies (18, 20, 36) relating hair dye use and non-Hodgkin lymphoma (NHL) have been published (37-52)(Table 3). These studies have varying conclusions, but the majority of case-control studies suggest a potential for elevated risk of NHL with hair dye use and cohort studies are somewhat mixed.
A pooled analysis by Zhang et al (53), which included studies (38, 39, 41, 43, 44) that have collected detailed information on personal hair dye use, noted a significantly increased risk of NHL in women who used hair dyes before 1980 (OR=1.3, 95% CI: 1.1, 1.4). Analyses by NHL subtype showed increased risk associated with follicular lymphoma (OR=1.4, 95% CI: 1.1, 1.9) and chronic/small lymphocytic leukemia (CLL/SLL) (OR=1.5, 95% CI: 1.1, 2.0) with a significant trend in risk with duration of use. No association was observed for other NHL subtypes. For women who began using the products in 1980 or after, an increased risk of follicular lymphoma was limited to users of dark-colored hair dyes (OR=1.5, 95%CI: 1.1,2.0). The results indicate that personal hair dye use may play a role in the risk of follicular lymphoma and CLL/SLL in women who started use before 1980 and that an increase in risk of follicular lymphoma in women starting use in 1980 or after cannot be excluded. The pooled analysis did not find an association among men.
Several studies also investigated effect modifications of genetic variation on the relationship between personal hair dye use and risk of NHL (39, 42, 48, 51) Schroeder et al (51) classified NHL by presence of t(14;18) translocation and found a significant risk for hair dye use in t(14;18)-negative translocation NHL (OR=2.1, 95%CI: 1.3,3.4) but not in t(14;18)-positive translocation NHL (OR=1.8, 95%CI: 0.9,3.7). Another study by Chiu et al (48), however, did not find an association by t(14;18) translocation in either men or women.
Morton et al. (39) examined the association by NAT1 and NAT2 genotype/phenotypes in a population-based multi-center case-control study involving 1,321 cases and 1,057 controls. They found an increased risk among women who used permanent intense tone hair dye products before 1980 if they had the rapid intermediate NAT2 phenotype (OR=3.3, 95%CI: 1.3,8.6) or the NAT1 10 allele (OR=2.5, 95%CI: 0.9,7.6), but not if they were slow NAT2 acetylators or had no copies of the NAT1 10 allele. NHL risk was not increased among women who began hair dye use after 1980 or among men.
A population-based case-control study among Connecticut women was conducted to test whether genetic variation in xenobiotic metabolic pathway genes modifies the relationship between hair dye use and risk of NHL (42). No effect modifications were found for women who started using hair dyes in 1980 or after. For women who started before 1980 compared to never users, a significantly increased risk of NHL overall was found for carriers of CYP2C9 Ex3-52C>T TT/CT genotypes (OR=2.9, 95%CI:1.4,6.1), CYP2E1 -332T>A AT/AA genotypes (OR=2.0, 95%CI:1.2,3.4), a homozygous or heterozygous 3bp deletion in intron 6 of GSTM3 (OR=2.3, 95%CI:1.3,4.1), GSTP1 Ex5-24A>G AA genotypes (OR=1.8, 95%CI:1.1,2.9), or NAT2 genotypes conferring intermediate/rapid acetylator status (OR=1.6, 95%CI: 1.0,2.7). The observed risks were strengthened and mainly observed for follicular lymphoma. In contrast, no significant increased risk was observed for hair dye users starting before 1980 relative to never users among women who were homozygous wild-type for the CYP2C9, CYP2E1, or GSTM3 polymorphisms, women carrying one or two copies of the variant GSTP1 allele, or women who were slow NAT2 acetylators.
6. HODGKIN'S DISEASE
Three case-control studies (40, 45, 50) and two cohort studies (20, 36) have investigated the relationship between hair dye use and risk of Hodgkin's disease. All of them have reported a non-significant inverse association except for one case-control study (40), which reported a three-fold increased risk of Hodgkin's disease associated with permanent hair dye use.
7. MULTIPLE MYELOMA
Two case-control studies suggested an increased risk of multiple myeloma associated with personal hair dye use (40, 54), while four studies found no association (45, 50, 55, 56)(Table 3). Brown reported a 1.9-fold increased risk of multiple myeloma among ever users based on 14 exposed cases. Zahm et al. (40) found that users of permanent hair dyes had about 3-fold increased risk of multiple myeloma.
The cohort studies provided inconsistent results linking hair dye use and risk of multiple myeloma (18-20, 36). Grodstein et al. (36) reported a reduced risk of multiple myeloma associated with personal hair dye use. Thun et al. (20) found a three-fold increased risk associated with dark permanent hair dye use. Mendelsohn et al. (18) noted no association between hair dye use and risk of multiple myeloma.
8. LEUKEMIA
Most studies suggested no association between leukemia risk and personal use of hair dyes (18, 20, 36, 50, 57), , while others suggested an inverse association (58) or positive association (37, 59). Study that examined the association by leukemia subtypes found no association with any subtype of leukemia (57).
In studies with a positive association of hair dye use and risk of leukemia, there is a possibility for increasing risk with darker and/or permanent hair dyes and longer duration of use. Miligi et al. (50) reported an increased risk of leukemia among women who reported using dark permanent hair dyes (OR=2.0, 95% CI: 1.1,3.8), although the study lacked information on time and duration of using hair dye products. Rauscher et al (59) reported an increased risk of leukemia associated with permanent hair dye use and the highest risk was found for women who used for 15 or more years up to six times per year of use.
Caution is necessary interpreting the inverse association noted in the Bjork et al (58) study. Information on use of hair dyes were obtained by proxy interview in 81% of cases and 14% of controls and no information on type, color, frequency or duration of hair coloring products was collected.
9. MYELODYSPLASTIC SYNDROMES
Ido et al. (60) conducted a hospital-based case-control study in Japan from 1992-93 to investigate the risk factors for myelodysplastic syndromes. No information on type or color of hair dyes, frequency or duration of use was collected in this study. A non-significant 2.5-fold increased risk (95% CI: 0.97, 6.41) was observed among women who had ever used hair dyes.
A hospital-based case-control study in Japan in 1995-96 investigated the association between hair dye use and risk of myelodysplastic syndromes (61). Ever use of hair dyes was significantly associated with the risk of myelodysplastic syndromes in both men and women (OR=2.0, 95%CI: 1.2,3.4) and in women only (OR=2.9, 95% CI: 1.4,6.0). The risks increased with increasing duration and number of hair dye uses. The study, however, provided no information on type or color of hair dye products used.
10. CANCERS AT OTHER SITES
A working group assessment by the Internal Agency for Research on Cancer (IARC) in 1993 assessed the risk of cancers of the cervix (7), ovary (7), lung (7), kidney (7), brain (62), salivary gland (63), and malignant melanoma (64, 65). Too few studies were available on those cancer sites to allow reviewers to make a conclusion whether personal hair dye use is associated with the risk of these cancer sites. More recently, however, a significant two-fold increased risk of ovarian cancer was observed for women who reported using hair dyes greater than 4 times per year and the risk increased with increasing frequency of hair dye use (P=0.007) (66). In one study of brain tumors, glioma risk was increased 1.7-fold (95% CI: 1.0, 2.9), and those who used permanent dye, a 2.4-fold increased risk (95% CI: 1.3, 4.5) (67). However, a large portion of cases were proxy interviews. In another brain tumor study no consistent association with any brain tumors (glioma, meningioma, and acoustic neuroma) was noted (68). Exposure assessment did not heavily rely on proxy interview as in the Heineman et al study (<18%)(67).
11. CHILDHOOD CANCERS
An investigation of Wilms Tumor risk, a childhood kidney tumor, was non-significantly increased with maternal use of hair dye products during pregnancy (OR=1.4, 95% CI: 0.7, 2.9) (69). Maternal use of hair dye products was not associated with the risk of childhood brain tumors in two studies (70, 71). But one study on maternal use of hair dyes and the risk of neuroblastoma in children identified an increased risk (OR=1.6, 95% CI: 1.2, 2.2) (72).
12. CONCLUSIONS
Epidemiological studies so far have provided limited evidence to support the hypothesis that personal use of hair dyes is associated with human cancer risk (73). However, a possible association between certain type or color of hair dye products, such as permanent dark color hair dyes, and certain subtype of cancers, such as bladder cancer and hematopoietic neoplasms, cannot be ruled out. Susceptible subgroups in the population may exist, such as certain functional polymorphisms in genes involved in arylamine activation or detoxification, which modify the association between hair dye use and human cancer risks.
Hematopoietic cancers appear to have a possible elevated risk associated with hair dye use. The strongest association appears to be with non-Hodgkin lymphoma where various studies have estimated the risk of up to 100% and even as high as 230% elevated risk for specific subtypes of NHL. Out of a total of 17 studies, 12 had significant results of elevated risk of NHL with hair dye use, while five other studies had elevated risk, though not statistically significant. Increased risk of NHL may be subtype specific. In several studies, when assessed by subtype, follicular lymphoma and CLL/SLL subtypes were elevated. Due to the different etiologies of most NHL, future studies should investigate NHL subtype and genetic polymorphisms in greater detail to better elucidate higher risk populations.
While a relationship between hair dye exposure and human cancer risk is biologically plausible, the results from epidemiological studies assessing hair dye use to human cancer risks have been inconsistent for nearly all cancer sites investigated. The major methodological challenge is exposure assessment. In most studies, hair dyes were just one of many exposure variables on which information was collected. In a few studies, only a few questions were asked to collect history regarding lifetime hair dye uses. This limited scope of exposure assessment diminishes an adequate characterization of exposure in terms of type or color of hair dyes, frequency or duration of use, time period of use, age during each period of use.
To further improve the value of epidemiologic research with regard to hair dye use will be an improvement in the methodology of both study design and exposure assessment. Prospective cohort studies have the importance of being able to several disease outcomes and to address temporal relationship. However, the published studies lacked complete information on timing, duration, frequency and type of hair dye product use, and this information is crucial to determining if intensity, total dose, type, and time period of hair dye use is most important in assessing risk.
In conclusion, the current evidence do not support a significant association between hair dye use and human cancer risk, except for the possibility of hematopoietic cancers. Given the complicated use patterns of hair dye products, the heterogeneity of many cancer sites, and the potential gene-environmental interactions, well-designed, large population-based studies could clarify the relationship between hair dyes and human cancer risks. Based on several recent studies, this relationship appears to be affected by specific genetic polymorphisms and future studies should investigate potential gene and environment interaction to assess possible genetic susceptibility.
13. REFERENCES
1. T Clausen, W Balzer: Hair colorant Chemistry. In: Hair in toxicology, an important bio-monitor. Ed D. J. Tobin. Royal Society of Chemistry, Cambridge (2005)
2. BN Ames, HO Kammen, E Yamasaki. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A, 72(6), 2423-7 (1975)
doi:10.1073/pnas.72.6.2423
3. M Gago-Dominguez, DA Bell, MA Watson, JM Yuan, JE Castelao, DW Hein, KK Chan, GA Coetzee, RK Ross, MC Yu. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis, 24(3), 483-9. (2003)
doi:10.1093/carcin/24.3.483
PMid:12663508
4. RJ Turesky, JP Freeman, RD Holland, DM Nestorick, DW Miller, DL Ratnasinghe, FF Kadlubar: Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol, 16(9), 1162-73. (2003)
doi:10.1021/tx030029r
PMid:12971805
5. M Jain, RW Morgan, L Elinson: Hair dyes and bladder cancer. Can Med Assoc J, 117(10), 1131-3 (1977)
PMid:603836 PMCid:1880297
6. CI Neutel, RC Nair, JM Last: Are hair dyes associated with bladder cancer? Can Med Assoc J, 119(4), 307-8 (1978)
PMid:688116 PMCid:1818315
7. KM Stavraky, EA Clarke, A Donner: A case-control study of hair-dye use and cancers of various sites. Br J Cancer, 43(2), 236-9 (1981)
doi:10.1038/bjc.1981.35
PMid:7470387 PMCid:2010516
8. P Hartge, R Hoover, R Altman, DF Austin, KP Cantor, MA Child, CR Key, TJ Mason, LD Marrett, MH Myers, AS Narayana, DT Silverman, JW Sullivan, GM Swanson, DB Thomas, DW West: Use of hair dyes and risk of bladder cancer. Cancer Res, 42(11), 4784-7 (1982)
PMid:7127313
9. GR Howe, JD Burch, AB Miller, GM Cook, J Esteve, B Morrison, P Gordon, LW Chambers, G Fodor, GM Winsor: Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst, 64(4), 701-13 (1980)
PMid:6928984
10. Y Ohno, K Aoki, K Obata, AS Morrison: Case-control study of urinary bladder cancer in metropolitan Nagoya. Natl Cancer Inst Monogr, 69, 229-34 (1985)
PMid:3834338
11. AS Andrew, AR Schned, JA Heaney, MR Karagas: Bladder cancer risk and personal hair dye use. Int J Cancer, 109(4), 581-6 (2004)
doi:10.1002/ijc.11729
PMid:14991581
12. J Lin, CP Dinney, HB Grossman, X Wu. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev, 15(9), 1746-9 (2006)
doi:10.1158/1055-9965.EPI-06-0156
13. M Kogevinas, F Fernandez, M Garcia-Closas, A Tardon, R Garcia-Closas, C Serra, A Carrato, G Castano-Vinyals, M Yeager, SJ Chanock, J Lloreta, N Rothman, FX Real, M Dosemeci, N Malats, D Silverman. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur J Cancer, 42(10), 1448-54 (2006)
doi:10.1016/j.ejca.2006.02.009
PMid:16740387
14. A Nomura, LN Kolonel, CN Yoshizawa: Smoking, alcohol, occupation, and hair dye use in cancer of the lower urinary tract. Am J Epidemiol, 130(6), 1159-63 (1989)
PMid:2589309
15. M Gago-Dominguez, JE Castelao, JM Yuan, MC Yu, RK Ross: Use of permanent hair dyes and bladder-cancer risk. Int J Cancer, 91(4), 575-9 (2001)
doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1092>3.0.CO;2-S
16. CH Hennekens, FE Speizer, B Rosner, CJ Bain, C Belanger, R Peto: Use of permanent hair dyes and cancer among registered nurses. Lancet, 1(8131), 1390-3 (1979)
doi:10.1016/S0140-6736(79)92021-X
17. SJ Henley, MJ Thun: Use of permanent hair dyes and bladder-cancer risk. Int J Cancer, 94(6), 903-6 (2001)
doi:10.1002/ijc.1547
PMid:11745498
18. JB Mendelsohn, QZ Li, BT Ji, XO Shu, G Yang, HL Li, KM Lee, K Yu, N Rothman, YT Gao, W Zheng, WH Chow: Personal use of hair dye and cancer risk in a prospective cohort of Chinese women. Cancer Sci, 100(6), 1088-91 (2009)
doi:10.1111/j.1349-7006.2009.01149.x
PMid:19385970 PMCid:2768318
19. SF Altekruse, SJ Henley, MJ Thun: Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes Control, 10(6), 617-25 (1999)
doi:10.1023/A:1008926027805
PMid:10616830
20. MJ Thun, SF Altekruse, MM Namboodiri, EE Calle, DG Myers, CW Heath, Jr.: Hair dye use and risk of fatal cancers in U.S. women. J Natl Cancer Inst, 86(3), 210-5 (1994)
doi:10.1093/jnci/86.3.210
21. M Huncharek, B Kupelnick. Personal use of hair dyes and the risk of bladder cancer: results of a meta-analysis. Public Health Rep, 120(1), 31-8 (2005)
PMid:15736329 PMCid:1497675
22. B Takkouche, M Etminan, A Montes-Martinez. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA, 293(20), 2516-25. (2005)
23. MA Kelsh, DD Alexander, RM Kalmes, PA Buffler. Personal use of hair dyes and risk of bladder cancer: a meta-analysis of epidemiologic data. Cancer Causes Control, 19(6), 549-58 (2008)
doi:10.1007/s10552-008-9123-z
PMid:283264
24. LJ Kinlen, R Harris, A Garrod, K. Rodriguez. Use of hair dyes by patients with breast cancer: a case-control study. Br Med J, 2(6083), 366-8 (1977)
PMid:480386
25. RE Shore, BS Pasternack, EU Thiessen, M Sadow, R Forbes, RE Albert: A case-control study of hair dye use and breast cancer. J Natl Cancer Inst, 62(2), 277-83 (1979)
26. KM Stavraky, EA Clarke, A Donner: Case-control study of hair dye use by patients with breast cancer and endometrial cancer. J Natl Cancer Inst, 63(4), 941-5 (1979)
PMid:6928044
27. PC Nasca, MS Baptiste, NA Field, BB Metzger, R DeMartino: An epidemiologic case-control study of breast cancer and exposure to hair dyes. Ann Epidemiol, 2(5), 577-86 (1992)
doi:10.1016/1047-2797(92)90002-8
PMid:6577224
28. PC Nasca, CE Lawrence, P Greenwald, S Chorost, JT Arbuckle, A Paulson: Relationship of hair dye use, benign breast disease, and breast cancer. J Natl Cancer Inst, 64(1), 23-8 (1980)
PMid:2035509
29. EL Wynder, M Goodman: Epidemiology of breast cancer and hair dyes. J Natl Cancer Inst, 71(3), 481-8 (1983)
PMid:10616824
30. KL Koenig, BS Pasternack, RE Shore, P Strax: Hair dye use and breast cancer: a case-control study among screening participants. Am J Epidemiol, 133(10), 985-95 (1991)
31. JD Boice Jr., JS Mandel, MM Doody: Breast cancer among radiologic technologists. JAMA, 274(5), 394-401 (1995)
PMid:11901963
32. LS Cook, KE Malone, JR Daling, LF Voigt, NS Weiss: Hair product use and the risk of breast cancer in young women. Cancer Causes Control, 10(6), 551-9 (1999)
doi:10.1023/A:1008903126798
PMid:3474457
33. T Zheng, TR Holford, ST Mayne, PH Owens, P Boyle, B Zhang, Y Zhang, SH Zahm. Use of hair colouring products and breast cancer risk: a case-control study in Connecticut. Eur J Cancer, 38(12), 1647-52 (2002)
doi:10.1016/S0959-8049(02)00138-7
34. W Petro-Nustas, ME Norton, I al-Masarweh: Risk factors for breast cancer in Jordanian women. J Nurs Scholarsh, 34(1), 19-25 (2002)
doi:10.1111/j.1547-5069.2002.00019.x
PMid:3354743 PMCid:1349342
35. A Green, WC Willett, GA Colditz, MJ Stampfer, C Bain, B Rosner, CH Hennekens, FE Speizer: Use of permanent hair dyes and risk of breast cancer. J Natl Cancer Inst, 79(2), 253-7 (1987)
PMid:9842372 PMCid:1509050
36. F Grodstein, CH Hennekens, GA Colditz, DJ Hunter, MJ Stampfer: A prospective study of permanent hair dye use and hematopoietic cancer. J Natl Cancer Inst, 86(19), 1466-70 (1994)
doi:10.1093/jnci/86.19.1466
PMid:17522066 PMCid:2085367
37. KP Cantor, A Blair, G Everett, S VanLier, L Burmeister, FR Dick, RW Gibson, L Schuman: Hair dye use and risk of leukemia and lymphoma. Am J Public Health, 78(5), 570-1 (1988)
doi:10.2105/AJPH.78.5.570
PMid:1609918 PMCid:1694062
38. EA Holly, C Lele, PM Bracci. Hair-color products and risk for non-Hodgkin's lymphoma: a population-based study in the San Francisco bay area. Am J Public Health, 88(12), 1767-73 (1998)
doi:10.2105/AJPH.88.12.1767
PMid:14718216
39. LM Morton, L Bernstein, SS Wang, DW Hein, N Rothman, JS Colt, S Davis, JR Cerhan, RK Severson, R Welch, P Hartge, SH Zahm: Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis, 28(8), 1759-64 (2007)
doi:10.1093/carcin/bgm121
PMid:19822571 PMCid:2781758
40. SH Zahm, DD Weisenburger, PA Babbitt, RC Saal, JB Vaught, A Blair: Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Am J Public Health, 82(7), 990-7 (1992)
doi:10.2105/AJPH.82.7.990
PMid:15914502
41. Y Zhang, TR Holford, B Leaderer, P Boyle, SH Zahm, S Flynn, G Tallini, PH Owens, T Zheng. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol, 159(2), 148-54. (2004)
doi:10.1093/aje/kwh033
PMid:16731576
42. Y Zhang, KJ Hughes, SH Zahm, TR Holford, L Dai, Y Bai, X Han, Q Qin, Q Lan, N Rothman, Y Zhu, B Leaderer, T Zheng: Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma. Am J Epidemiol, 170(10), 1222-30 (2009)
doi:10.1093/aje/kwp263
PMid:15389468
43. Y Benavente, N Garcia, E Domingo-Domenech, T Alvaro, R Font, Y Zhang, S de Sanjose: Regular use of hair dyes and risk of lymphoma in Spain. Int J Epidemiol, 34(5), 1118-22 (2005)
doi:10.1093/ije/dyi109
PMid:7617081
44. S de Sanjose, Y Benavente, A Nieters, L Foretova, M Maynadie, PL Cocco, A Staines, M Vornanen, P Boffetta, N Becker, T Alvaro, P Brennan: Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am J Epidemiol, 164(1), 47-55. Epub 2006 May 26. (2006)
doi:10.1093/aje/kwj187
PMid:15066915
45. A Tavani, E Negri, S Franceschi, R Talamini, D Serraino, C La Vecchia: Hair dye use and risk of lymphoid neoplasms and soft tissue sarcomas. Int J Cancer, 113(4), 629-31. (2005)
doi:10.1002/ijc.20565
PMid:17204518
46. L Markovic-Denic, S Jankovic, J Marinkovic, Z Radovanovic: Brick mortar exposure and chronic lymphocytic leukemia. Neoplasma, 42(2), 79-81 (1995)
47. BC Chiu, DD Weisenburger, SH Zahm, KP Cantor, SM Gapstur, F Holmes, LF Burmeister, A Blair: Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 13(4), 525-31 (2004)
48. BC Chiu, BJ Dave, A Blair, SM Gapstur, JS Chmiel, AJ Fought, SH Zahm, DD Weisenburger: Cigarette smoking, familial hematopoietic cancer, hair dye use, and risk of t(14;18)-defined subtypes of non-Hodgkin's lymphoma. Am J Epidemiol, 165(6), 652-9 (2007)
doi:10.1093/aje/kwk044
PMid:15914752
49. L Miligi, AS Costantini, A Benvenuti, A Veraldi, R Tumino, V Ramazzotti, C Vindigni, D Amadori, A Fontana, S Rodella, E Stagnaro, P Crosignani, P Vineis: Personal use of hair dyes and hematolymphopoietic malignancies. Arch Environ Occup Health, 60(5), 249-56 (2005)
doi:10.3200/AEOH.60.5.249-256
PMid:890298 PMCid:1631150
50. L Miligi, A Seniori Costantini, P Crosignani, A Fontana, G Masala, O Nanni, V Ramazzotti, S Rodella, E Stagnaro, R Tumino, C Vigano, C Vindigni, P Vineis: Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. Am J Ind Med, 36(1), 60-9 (1999)
doi:10.1002/(SICI)1097-0274(199907)36:1<60::AID-AJIM9>3.0.CO;2-Z
PMid:7616635
51. JC Schroeder, AF Olshan, R Baric, GA Dent, CR Weinberg, B Yount, JR Cerhan, CF Lynch, LM Schuman, PE Tolbert, N Rothman, KP Cantor, A Blair: A case-control study of tobacco use and other non-occupational risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma (United States). Cancer Causes Control, 13(2), 159-68 (2002)
doi:10.1023/A:1014397920185
PMid:11936822
52. O Wong, F Harris, Y Wang, H Fu. A hospital-based case-control study of non-Hodgkin lymphoid neoplasms in Shanghai: analysis of personal characteristics, lifestyle, and environmental risk factors by subtypes of the WHO classification. J Occup Environ Med, 52(1), 39-53 (2010)
doi:10.1097/JOM.0b013e3181c5c399
PMid:20042883
53. Y Zhang, SD Sanjose, PM Bracci, LM Morton, R Wang, P Brennan, P Hartge, P Boffetta, N Becker, M Maynadie, L Foretova, P Cocco, A Staines, T Holford, EA Holly, A Nieters, Y Benavente, L Bernstein, SH Zahm, T Zheng: Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol, 167(11), 1321-31 (2008)
doi:10.1093/aje/kwn058
PMid:18408225
54. LM Brown, GD Everett, LF Burmeister, A Blair: Hair dye use and multiple myeloma in white men. Am J Public Health, 82(12), 1673-4 (1992)
doi:10.2105/AJPH.82.12.1673
PMid:1456346 PMCid:1694533
55. LJ Herrinton, NS Weiss, TD Koepsell, JR Daling, JW Taylor, JL Lyon, GM Swanson, RS Greenberg: Exposure to hair-coloring products and the risk of multiple myeloma. Am J Public Health, 84(7), 1142-4 (1994)
doi:10.2105/AJPH.84.7.1142
PMid:8017540 PMCid:1614739
56. S Koutros, D Baris, E Bell, T Zheng, Y Zhang, TR Holford, BP Leaderer, O Landgren, SH Zahm: Use of hair colouring products and risk of multiple myeloma among US women. Occup Environ Med, 66(1), 68-70 (2009)
doi:10.1136/oem.2008.041053
PMid:18805876 PMCid:2756225
57. A Mele, M Szklo, G Visani, MA Stazi, G Castelli, P Pasquini, F Mandelli. Hair dye use and other risk factors for leukemia and pre-leukemia: a case-control study. Italian Leukemia Study Group. Am J Epidemiol, 139(6), 609-19 (1994)
PMid:8172172
58. J Bjork, M Albin, H Welinder, H Tinnerberg, N Mauritzson, T Kauppinen, U Stromberg, B Johansson, R Billstrom, Z Mikoczy, T Ahlgren, PG Nilsson, F Mitelman, L Hagmar: Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med, 58(11), 722-7 (2001)
doi:10.1136/oem.58.11.722
PMid:11600728 PMCid:1740065
59. GH Rauscher, D Shore, DP Sandler: Hair dye use and risk of adult acute leukemia. Am J Epidemiol, 160(1), 19-25 (2004)
doi:10.1093/aje/kwh166
PMid:15229113
60. M Ido, C Nagata, N Kawakami, H Shimizu, Y Yoshida, T Nomura, H Mizoguchi: A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res, 20(9), 727-31 (1996)
doi:10.1016/0145-2126(96)00042-2
61. C Nagata, H Shimizu, K Hirashima, E Kakishita, K Fujimura, Y Niho, M Karasawa, S Oguma, Y Yoshida, H Mizoguchi: Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res, 23(1), 57-62 (1999)
doi:10.1016/S0145-2126(98)00135-0
62. JD Burch, KJ Craib, BC Choi, AB Miller, HA Risch, GR Howe: An exploratory case-control study of brain tumors in adults. J Natl Cancer Inst, 78(4), 601-9 (1987)
PMid:3104645
63. MR Spitz, JJ Fueger, H Goepfert, GR Newell: Salivary gland cancer. A case-control investigation of risk factors. Arch Otolaryngol Head Neck Surg, 116(10), 1163-6 (1990)
PMid:2206501
64. CD Holman, BK Armstrong: Hutchinson's melanotic freckle melanoma associated with non-permanent hair dyes. Br J Cancer, 48(4), 599-601 (1983)
doi:10.1038/bjc.1983.234
PMid:6626457 PMCid:2011484
65. A Osterlind, MA Tucker, BJ Stone, OM Jensen: The Danish case-control study of cutaneous malignant melanoma. IV. No association with nutritional factors, alcohol, smoking or hair dyes. Int J Cancer, 42(6), 825-8 (1988)
PMid:3192325
66. A Tzonou, A Polychronopoulou, CC Hsieh, A Rebelakos, A Karakatsani, D Trichopoulos: Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer, 55(3), 408-10 (1993)
doi:10.1002/ijc.2910550313
67. EF Heineman, MH Ward, RD McComb, DD Weisenburger, SH Zahm: Hair dyes and risk of glioma among Nebraska women. Cancer Causes Control, 16(7), 857-64 (2005)
doi:10.1007/s10552-005-3204-z
68. EC Bluhm, SH Zahm, HA Fine, PM Black, JS Loeffler, WR Shapiro, RG Selker, PD Inskip: Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults. Am J Epidemiol, 165(1), 63-71 (2007)
doi:10.1093/aje/kwk002
PMid:17079691
69. AF Olshan, NE Breslow, JM Falletta, S Grufferman, T Pendergrass, LL Robison, M Waskerwitz, WG Woods, TJ Vietti, GD Hammond: Risk factors for Wilms tumor. Report from the National Wilms Tumor Study. Cancer, 72(3), 938-44 (1993)
doi:10.1002/1097-0142(19930801)72:3<938::AID-CNCR2820720345>3.0.CO;2-C
70. GR Bunin, JD Buckley, CP Boesel, LB Rorke, AT Meadows: Risk factors for astrocytic glioma and primitive neuroectodermal tumor of the brain in young children: a report from the Children's Cancer Group. Cancer Epidemiol Biomarkers Prev, 3(3), 197-204 (1994)
PMid:8019366
71. EA Holly, PM Bracci, MK Hong, BA Mueller, S Preston-Martin: West Coast study of childhood brain tumours and maternal use of hair-colouring products. Paediatr Perinat Epidemiol, 16(3), 226-35 (2002)
doi:10.1046/j.1365-3016.2002.00420.x
PMid:12123435
72. EE McCall, AF Olshan, JL Daniels: Maternal hair dye use and risk of neuroblastoma in offspring. Cancer Causes Control, 16(6), 743-8 (2005)
doi:10.1007/s10552-005-1229-y
73. R Baan, K Straif, Y Grosse, B Secretan, F El Ghissassi, V Bouvard, L Benbrahim-Tallaa, V Cogliano: Carcinogenicity of some aromatic amines, organic dyes, and related exposures. Lancet Oncol, 9(4), 322-3 (2008)
doi:10.1016/S1470-2045(08)70089-5
Key Words: Hair Dye, Cancer, Noeplasia, Tumor, Epidemiology, Review
Send correspondence to: Yawei Zhang, Yale University School of Public Health, 60 College Street LEPH 440, New Haven, CT 06520, Tel: 203-785-6210, Fax: 203-737-6023, E-mail:yawei.zhang@yale.edu